Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0001209191-23-038744

Chief Commercial Officer acquired 6,250 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Simon Farrell · Chief Commercial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-06-20 Exercise or conversion : show line 1 in the form +6,250 $0.51 $3,194 45,650 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-06-20 Exercise or conversion : show line 2 in the form Stock Option (right to buy) −6,250 50,000 D
Loading xslF345X04/doc4.xml…